M. Spielmann

发表

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.

S. Michiels, F. André, P. Dessen, 2009, The Lancet. Oncology.

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review

Pierre-Marie Martin, Carole Mathelin, Fabrice André, 2011, Breast Cancer Research and Treatment.

Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients.

B. Plaud, S. Bonvalot, M. Ducreux, 1998, Journal of the American College of Surgeons.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.

R. Arriagada, T. Delozier, M. Namer, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1 146 patients with early breast cancer

R. Arriagada, T. Delozier, S. Koscielny, 2005, Acta oncologica.

Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group.

T. Delozier, J. Petit, B. Weber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

L. Zelek, A. Le Cesne, M. Spielmann, 2001, Cancer.

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

L. Zelek, A. Le Cesne, M. Spielmann, 2001 .

Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: the AnemOnHe study.

I. Ray-Coquard, S. de Botton, M. Spielmann, 2012, European journal of cancer.

3D-conformal Accelerated Partial Breast Irradiation treatment planning: the value of surgical clips in the delineation of the lumpectomy cavity

A. Dunant, H. Marsiglia, M. Spielmann, 2009, Radiation oncology.

Surgical and chemotherapeutic treatment of hepatic metastases from carcinoma of the breast.

D. Elias, P. Lasser, M. Spielmann, 1991, Surgery, gynecology & obstetrics.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy.

M. Mathieu, F. André, W. Symmans, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

T. Delozier, J. Bonneterre, B. Asselain, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen.

R. Arriagada, T. Delozier, S. Koscielny, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis.

M. Namer, D. Dodwell, C. Unger, 2001, Clinical breast cancer.

Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.

D. Lacombe, T. Tursz, M. Spielmann, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.

A. Cesne, A. Le Cesne, X. Pivot, 1998, British Journal of Cancer.

Primary Breast Sarcomas

L. Zelek, A. Cesne, M. Spielmann, 2009 .

Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up.

L. Zelek, P. Terrier, A. Cesne, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer with synchronous metastases: trends in survival during a 14-year period.

R. Rouzier, M. Namer, F. André, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term effect of internal mammary chain treatment. Results of a multivariate analysis of 1195 patients with operable breast cancer and positive axillary nodes.

R. Arriagada, M. Tubiana, M. Spielmann, 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Does malignant small round cell tumor of the thoracopulmonary region (askin tumor) constitute a clinicopathologic entity?. An analysis of 30 cases with immunohistochemical and electron‐microscopic support treated at the institute gustave roussy

A. Llombart‐Bosch, P. Terrier, J. Habrand, 1992, Cancer.

Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study.

P. Viens, P. Fumoleau, P. Marino, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of a combination of elliptinium and vinblastine in metastatic breast cancer

T. Tursz, T. Chevalier, M. Spielmann, 1992, Investigational New Drugs.

Risk factors for brain relapse in patients with metastatic breast cancer.

F. André, A. Dunant, M. Spielmann, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

The natural history of breast carcinoma in patients with ≥ 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy

G. Hortobagyi, S. Singletary, J. Garcia-conde, 2005, Cancer.

Hypothyroidism and goiter during interleukin-2 therapy

M. Schlumberger, T. Tursz, T. Chevalier, 1990, Journal of endocrinological investigation.

Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer.

L. Mauriac, J. Canon, G. Romieu, 2009 .

Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis.

L. Zelek, J. Laredo, M. Namer, 2009, Critical reviews in oncology/hematology.

Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes.

L. Zelek, M. Spielmann, K. Fizazi, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer

M. Espié, M. Namer, P. Fumoleau, 2001, Oncology.

Liver metastases from extremity soft tissue sarcoma.

P. Terrier, A. Le Cesne, O. Merimsky, 1999, American journal of clinical oncology.

Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged <35 years

M. Namer, B. Asselain, M. Spielmann, 2009, Cancer.

Prognostic F actors i n P rimary B reast S arcomas: A S eries o f Patients W ith L ong-Term F ollow-Up

L. Zelek, P. Terrier, A. Cesne, 2003 .

Surgical resection of pulmonary metastases. Up to what number?

T. le Chevalier, M. Spielmann, P. Girard, 1994, American journal of respiratory and critical care medicine.

Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy.

D. Vanel, M. Spielmann, D. Couanet, 1987, Radiology.

Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines.

L. Zelek, M. Namer, A. Lluch, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience.

J. Droz, M. Spielmann, P. Fargeot, 1991, European journal of cancer.

p53 protein overexpression and chemosensitivity in breast cancer

T. Powles, M. Dowsett, R. Arriagada, 1995, The Lancet.

Quality of life after sentinel lymph node biopsy in early breast cancer.

R. Rouzier, M. Mathieu, H. Marsiglia, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.

V. Diéras, M. Spielmann, P. Pouillart, 1996, Seminars in oncology.

Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy

S. Dauchy, C. Charles, M. Spielmann, 2015, Supportive Care in Cancer.

p53 protein overexpression and chemosensitivity in breast cancer. Institut Gustave-Roussy Breast Cancer Group.

R. Arriagada, M. Mathieu, S. Koscielny, 1995, The Lancet.

A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.

J. Bonneterre, M. Tubiana-Hulin, M. Spielmann, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors

S. Friedman, M. Spielmann, H. Mouriesse, 1990, Breast Cancer Research and Treatment.

Association of c‐erbB2‐gene amplification with poor prognosis in non‐inflammatory breast carcinomas but not in carcinomas of the inflammatory type

J. Ahomadégbé, G. Riou, M. Spielmann, 1994, International journal of cancer.

Twenty-year results of alternating radiotherapy and chemotherapy in nonmetastatic inflammatory breast cancer.

R. Arriagada, M. Mathieu, A. Dunant, 2010 .

Use of molecular classification combined with p53 and topoisomerase IIa expression to identify tumors highly responsive to FEC regimen: A tissue microarray.

F. André, M. Spielmann, S. Delaloge, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Choroid metastases: Clinical features and treatments in 123 patients

R. Arriagada, M. Spielmann, MoniqueG. Lê, 2003, Cancer.

Phase II trial of 3D-conformal accelerated partial breast irradiation: lessons learned from patients and physicians' evaluation.

A. Taghian, H. Marsiglia, M. Spielmann, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer.

L. Zelek, A. Cesne, A. Le Cesne, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Taxol (paclitaxel) in patients with metastatic breast carcinoma who have failed prior chemotherapy: interim results of a multinational study.

M. Spielmann, 1994, Oncology.

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

K. Gelmon, M. Namer, J. Bonneterre, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Alternating chemotherapy and hyperfractionated accelerated radiotherapy in non-metastatic inflammatory breast cancer].

L. Zelek, R. Arriagada, J. Habrand, 2000, Cancer Radiothérapie.

Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial.

T. Delozier, M. Campone, T. Petit, 2009 .

Short term vs lifelong adjuvant tamoxifen in early breast cancer (EBC): A randomized trial (TAM-01)

T. Delozier, J. Petit, B. Weber, 1997 .

Prognostic role of serum Ca 15-3 and circumstances of diagnostic in advanced breast cancer: Data from a prospective randomized trial.

R. Arriagada, R. Rouzier, M. Mathieu, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Metastases from cancers of unknown primary site. Data from 302 autopsies].

A. Le Cesne, T. le Chevalier, M. Spielmann, 1991, Presse medicale.

Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer

M. Mathieu, B. Caillou, J. Bosq, 2005, Breast Cancer Research and Treatment.

Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?

G. Vassal, A. Le Cesne, T. Tursz, 1999, Journal of immunotherapy.

Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients.

T. Chevalier, T. le Chevalier, M. Spielmann, 1988, Archives of internal medicine.

Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.

D. Lacombe, T. Tursz, J. Armand, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Angiosarcoma of the breast after conservative surgery and radiation therapy for breast carcinoma: three new cases.

M. Spielmann, G. Contesso, J. Molitor, 1996, European journal of cancer.

Docetaxel chemotherapy induces transverse superficial loss of the nail plate.

X. Pivot, A. Llombart-Cussac, M. Spielmann, 1997, Archives of dermatology.

[Angiosarcoma of the breast. Apropos of 8 cases and review of the literature].

L. Zelek, T. le Chevalier, M. Spielmann, 1997, Bulletin du cancer.

[Factors of severity in placental choriocarcinoma].

T. Tursz, J. Droz, M. Spielmann, 1982, Journal de gynecologie, obstetrique et biologie de la reproduction.

Primary breast sarcoma: A review of 33 cases with immunohistochemistry and prognostic factors

S. Friedman, P. Terrier, M. Spielmann, 2005, Breast Cancer Research and Treatment.

Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.

J. Lemonnier, M. Lacroix-Triki, M. Campone, 2015, Future oncology.

Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer

L. Zitvogel, G. Kroemer, F. André, 2015, Autophagy.

CXCR4 expression in early breast cancer and risk of distant recurrence.

G. Hortobagyi, L. Pusztai, R. Arriagada, 2009, The oncologist.

[Cellular immunity in breast cancer patients].

M. Spielmann, H. Kitschke, K. Tietje, 1982, Onkologie.

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

J. Machiels, F. Penault-Llorca, B. Asselain, 2012, The oncologist.

[The use of deodorants/antiperspirants does not constitute a risk factor for breast cancer].

M. Namer, M. Spielmann, J. Gligorov, 2008, Bulletin du cancer.

Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer.

R. Arriagada, T. Chevalier, T. le Chevalier, 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy

R. Arriagada, T. Tursz, T. Chevalier, 1995, Cancer.

Alternating radiotherapy and chemotherapy in non-metastatic inflammatory breast cancer.

R. Arriagada, T. le Chevalier, M. Spielmann, 1990, International journal of radiation oncology, biology, physics.

Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations

S. Richard, O. Cussenot, A. Cambon-Thomsen, 2018, European Journal of Human Genetics.

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

J. Cuzick, J. Bergh, R. Peto, 2021, The Lancet. Oncology.

An attempt to clarify indications for hepatectomy for liver metastases from breast cancer.

M. Druet‐Cabanac, D. Elias, M. Spielmann, 2003, American journal of surgery.

Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations

S. Richard, O. Cussenot, A. Cambon-Thomsen, 2018, European Journal of Human Genetics.

Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer.

R. Arriagada, M. Spielmann, G. Contesso, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.

A. Cesne, A. Le Cesne, N. Janin, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

M. Espié, M. Mathieu, M. Marty, 2010, Breast Cancer Research and Treatment.

High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer

B. Asselain, L. Mauriac, P. Fumoleau, 2011, British Journal of Cancer.

Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials.

R. Arriagada, S. Michiels, F. André, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.

F. Penault-Llorca, R. Boidot, P. Fumoleau, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[CA 15-3 and breast cancer].

M. Spielmann, E. Antoine, L. Kayitalire, 1994, La Revue de medecine interne.

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial

F. Penault-Llorca, J. Lemonnier, J. Canon, 2013, Breast Cancer Research and Treatment.

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

E. Perez, R. Gelber, J. Costantino, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Structure and expression of c‐erbB‐2 and EGF receptor genes in inflammatory and non‐inflammatory breast cancer: Prognostic significance

M. Mathieu, G. Riou, M. Spielmann, 1989, International journal of cancer.

The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile.

R. Rouzier, M. Mathieu, S. Koscielny, 2004, European journal of cancer.

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

J. Machiels, T. Delozier, F. Penault-Llorca, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors of young women (≤ 35 years) with node positive breast cancer: possible influence on post-therapeutic follow-up.

J. Canon, P. Fumoleau, Anne-Laure Martin, 2013, Bulletin du cancer.

Preoperative induction chemotherapy in the treatment of locally advanced soft tissue sarcomas

T. le Chevalier, M. Spielmann, G. Contesso, 1987, Cancer.

Acute Antiemetic Efficacy and Safety of Dolasetron Mesylate, A 5‐HT3 Antagonist, in Cancer Patients Treated with Cisplatin

T. Conroy, G. Prévot, M. Spielmann, 1994, American journal of clinical oncology.

Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.

M. Mathieu, F. André, J. Soria, 2007, Anticancer research.

[Malignant lymphomas and other hematosarcomas with initial breast localization. Retrospective study of 20 cases].

B. Caillou, M. Spielmann, G. Contesso, 1983, Bulletin du cancer.

Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma.

P. Terrier, S. Bonvalot, O. Mir, 2011, European journal of cancer.

Salvage chemotherapy in refractory germ cell tumors with etoposide (vp‐16) plus ifosfamide plus high‐dose cisplatin. A vihp regimen

C. Théodore, J. Droz, M. Spielmann, 1988, Cancer.

Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study.

M. Spielmann, G. Falkson, H. Bleiberg, 1995, Clinical therapeutics.

Phase II study of elliptinium acetate salvage treatment of advanced breast cancer.

T. le Chevalier, M. Spielmann, M. Azab, 1993, European Journal of Cancer.

Phase II study of elliptinium in advanced breast cancer.

T. le Chevalier, M. Spielmann, H. Sancho-garnier, 1985, Cancer treatment reports.

A phase I trial with recombinant interferon γ (Roussel UCLAF) in advanced cancer patients

T. Tursz, T. Chevalier, M. Spielmann, 2005, Cancer Immunology, Immunotherapy.

Activity of gemcltabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containlng regimens

M. Espié, M. Namer, P. Fumoleau, 1997 .

Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer.

M. Mathieu, F. André, M. Spielmann, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for death after an isolated local recurrence in patients with early‐stage breast carcinoma

Rodrigo Arriagada, R. Arriagada, M. Spielmann, 2002, Cancer.

Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.

J. Bonneterre, V. Diéras, M. Spielmann, 1997, Seminars in oncology.

Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'.

L. Zelek, M. Spielmann, G. Freyer, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Hepatectomy for liver metastases from breast cancer.

D. Elias, P. Lasser, M. Spielmann, 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

H. Wildiers, J. Lemonnier, M. Lacroix-Triki, 2018, European journal of cancer.

Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy.

S. Friedman, R. Arriagada, T. Chevalier, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

A. Vincent-Salomon, T. Delozier, M. Namer, 2010, The oncologist.

Safety analysis from PACS 04-A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+ patients: Preliminary results.

T. Delozier, B. Asselain, J. Canon, 2006, Journal of Clinical Oncology.

c‐myc, p53 and bcl‐2, apoptosis‐related genes in infiltrating breast carcinomas: Evidence of a link between bcl‐2 protein over‐expression and a lower risk of metastasis and death in operable patients

M. Mathieu, G. Riou, M. Spielmann, 1999, International journal of cancer.

First-Line Vinorelbine-Mitoxantrone Combination in Metastatic Breast Cancer Patients Relapsing after an Adjuvant Anthracycline Regimen: Results of a Phase II Study

A. Le Cesne, X. Pivot, T. Tursz, 1998, Oncology.

Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients.

R. Arriagada, T. Tursz, M. Spielmann, 2005, Clinical breast cancer.

Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.

Roman Rouzier, Lajos Pusztai, Kenneth R Hess, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conservative management of breast cancer

R. Arriagada, T. Chevalier, T. le Chevalier, 1986, The British journal of surgery.

Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.

R. Arriagada, M. Mathieu, A. Dunant, 2012, International journal of radiation oncology, biology, physics.

Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer.

D. Rimm, S. Michiels, F. André, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer.

L. Pusztai, S. Michiels, R. Nahta, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of high dose ifosfamide plus mesna in inoperable non small cell lung carcinoma.

R. Arriagada, T. le Chevalier, J. Droz, 1988, European journal of cancer & clinical oncology.

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes.

F. Penault-Llorca, F. André, F. Bidard, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[Soft tissue sarcomas: general review].

A. Le Cesne, T. Tursz, T. le Chevalier, 1994, Bulletin du Cancer.

Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.

P. Fumoleau, Anne-Laure Martin, M. Spielmann, 2014, European journal of cancer.

Breast‐conserving surgery after neoadjuvant anthracycline‐based chemotherapy for large breast tumors

Roman Rouzier, Fabrice André, R. Rouzier, 2004, Cancer.

Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.

P. Fumoleau, Anne-Laure Martin, F. Dalenc, 2012, Bulletin du cancer.

Prognostic importance of low c-erbB2 expression in breast tumors.

P. Terrier, S. Koscielny, M. Spielmann, 1998, Journal of the National Cancer Institute.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.

M. Namer, J. Bonneterre, J. Zalcberg, 1996, British Journal of Cancer.

A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

L. Zelek, M. Spielmann, E. Brain, 2006, British Journal of Cancer.

Pirarubicin in advanced breast cancer: a French cooperative phase II study.

T. Delozier, M. Namer, A. Monnier, 1990, European journal of cancer.

1200 Adults with Ewing's sarcoma: A retrospective study of 146 cases

A. Cesne, T. Tursz, N. Dohollou, 1995 .

Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial

M Namer, M. Namer, M. Tubiana-Hulin, 2002, British Journal of Cancer.

Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.

L. Zelek, S. Culine, M. Tubiana-Hulin, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum neuron-specific enolase (NSE) as a tumour marker for the Ewing's sarcoma family of tumours.

A. Le Cesne, T. le Chevalier, N. Dohollou, 1996, European journal of cancer.

BRCA1 germ-line mutation: Predictive of sensitivity to anthracyclin alkylating agents regimens but not to taxanes?

F. André, F. Bidard, M. Spielmann, 2008 .

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer.

M. Spielmann, Amr Yehia Sakr, Y. A. Kader, 2013, Breast cancer.

[Synchronous cancers of the esophagus and of the ORL area: results of combined treatments with esophagectomy (28 cases)].

D. Elias, P. Lasser, M. Spielmann, 1991, Bulletin du cancer.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Effect of pregnancy, in the year prior and after treatment for breast carcinoma, on survival and recurrence in women with breast cancer younger than 35 years. GETNA GROUP.

M. Namer, B. Asselain, M. Spielmann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer in young women age < 36 years: A retrospective analysis of prognostic factors in 926 patients in 8 french instituitions. GETNA group

M. Namer, F. Penault-Llorca, B. Asselain, 2005 .

A Before-After Study Using OncoDoc, a Guideline-Based Decision Support-System on Breast Cancer Management: Impact upon Physician Prescribing Behaviour

Jacques Bouaud, Brigitte Séroussi, Éric-Charles Antoine, 2001, MedInfo.

Individualized Prediction of Menses Recovery After Chemotherapy for Early‐stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials

J. Lemonnier, M. Campone, B. Pistilli, 2019, Clinical breast cancer.

[Treatment of advanced breast cancer in postmenopausal women with droloxifene: results of a double-blind phase II trial for dose determination].

M. Marty, M. Spielmann, P. Pouillart, 1993, Bulletin du Cancer.

Phase II study of 4'epirubicin in advanced squamous cell oesophageal cancer.

P. Rougier, D. Elias, M. Spielmann, 1994, European journal of cancer.

[Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].

F. André, M. Spielmann, S. Delaloge, 2009, Bulletin du cancer.

[Node negative breast cancer. Beyond international consensus: a pragmatic approach].

T. Delozier, M. Namer, F. Penault-Llorca, 2011, Bulletin du cancer.

[Initial chemotherapy in the treatment of inflammatory breast cancers. 230 cases].

R. Arriagada, T. le Chevalier, M. Spielmann, 1987, Presse medicale.

Neoadjuvant chemotherapy in multiple synchronous head and neck and esophagus squamous cell carcinomas

J. Armand, M. Spielmann, E. Cvitkovic, 1992, The Laryngoscope.

P. Terrier, J. Habrand, T. Tursz, 1992, Cancer.

STRUCTURE AND EXPRESSION OF c-erbB-2 AND EGF RECEPTOR GENES PROGNOSTIC SIGNIFICANCE IN INFLAMMATORY AND NON-INFLAMMATORY BREAST CANCER:

M. Mathieu, M. Spielmann, M. Guérin, 2006 .

Phase II study of pirarubicin in advanced non-small cell lung cancer.

R. Arriagada, P. Hérait, T. Tursz, 1989, European Journal of Cancer and Clinical Oncology.

Cxcr4 expression and risk of bone metastasis in patients with early breast cancer

G. Hortobagyi, S. Michiels, F. André, 2007 .

[A multivariate prospective study of prognostic factors in 200 operated epidermoid cancers of the esophagus. Definition of patients for whom surgical resection was of benefit].

B. Escudier, D. Elias, P. Lasser, 1993, Gastroenterologie clinique et biologique.